Sutro Biopharma, INC Form 4 insider transactions

Sutro Biopharma, Inc. director Jon Marc Wigginton was granted stock options for 10,000 shares of common stock.

Sutro Biopharma director Daniel H. Petree acquired 10,000 stock options with an exercise price of $26.09, vesting over time with full vesting by June 5, 2027.

James P. Panek, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options with an exercise price of $26.09.

Sutro Biopharma Director Joseph M. Lobacki acquired 10,000 stock options with an exercise price of $26.09, vesting over time with full vesting by June 5, 2027.

Sutro Biopharma director Jagpal Sukhi was granted 10,000 stock options with an exercise price of $26.09, vesting over time.

Heidi Hunter, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options with an exercise price of $26.09.

Michael Dybbs, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options with an exercise price of $26.09.

Sutro Biopharma Director Connie Matsui acquired 10,000 stock options with an exercise price of $26.09.

Sutro Biopharma CFO Gregory K. Chow acquired 2,500 shares of common stock and 2,500 Restricted Stock Units (RSUs) on June 2, 2026.

Sutro Biopharma's Chief Administrative Officer, David Pauling, reported the vesting of 675 Restricted Stock Units and the subsequent withholding of 277 shares for tax obligations.

Sutro Biopharma CEO Jane Chung reported the vesting and net settlement of 788 restricted stock units, increasing her direct common stock ownership.

Sutro Biopharma's Chief Administrative Officer and General Counsel, David Pauling, reported recent equity transactions including RSU settlements and new grants, all adjusted for a 1-for-10 reverse stock split.

Sutro Biopharma's Chief Scientific Officer, Hans-Peter Gerber, reported the acquisition of common stock through RSU settlements and subsequent tax-related dispositions, alongside new RSU and stock option grants.

Sutro Biopharma's CFO, Gregory K. Chow, received new equity awards comprising stock options and restricted stock units, following a recent 1-for-10 reverse stock split.

Sutro Biopharma's CEO and Director, Jane Chung, reported significant equity transactions including the vesting of restricted stock units and new grants of RSUs and stock options.

Sutro Biopharma director Jon Marc Wigginton was granted 1,500 stock options with an exercise price of $10.38, vesting monthly over six months.

Sutro Biopharma director Daniel H. Petree was granted 1,500 stock options with an exercise price of $10.38, vesting monthly over six months.

Sutro Biopharma director James P. Panek received a grant of 1,500 stock options with an exercise price of $10.38, vesting monthly over approximately six months.

Sutro Biopharma Director Connie Matsui received a grant of 1,500 stock options with a $10.38 exercise price, vesting monthly over six months.

Sutro Biopharma Director Joseph M. Lobacki was granted 1,500 stock options with an exercise price of $10.38, vesting monthly starting January 23, 2026.

Sutro Biopharma Director Sukhi Jagpal was granted 1,500 stock options with an exercise price of $10.38, vesting monthly over six months.

Sutro Biopharma director Heidi Hunter received a grant of 1,500 stock options with an exercise price of $10.38, vesting monthly over six months.

Sutro Biopharma director Michael Dybbs was granted 1,500 stock options with an exercise price of $10.38, vesting monthly starting January 23, 2026.

Sutro Biopharma's Chief Administrative Officer and General Counsel, David Pauling, was granted 7,200 stock options with an exercise price of $10.38, vesting monthly over four years.

Sutro Biopharma's Chief Scientific Officer, Hans-Peter Gerber, was granted 7,925 stock options with a $10.38 exercise price, vesting monthly over four years.

Sutro Biopharma's CFO, Gregory K. Chow, was granted 8,200 stock options with a vesting schedule over 48 months.

Sutro Biopharma's CEO and Director, Jane Chung, reported the settlement of Restricted Stock Units and related tax withholding, following a 1-for-10 reverse stock split.

Sutro Biopharma's Chief Scientific Officer, Hans-Peter Gerber, acquired 17,000 shares of common stock at a weighted average price of $0.8004.

Sutro Biopharma's CFO, Gregory K. Chow, purchased 19,750 shares of common stock at a weighted average price of $0.81 per share.

Sutro Biopharma's CEO, Jane Chung, acquired 12,500 shares of common stock at $0.8009 per share, increasing her direct beneficial ownership to 122,850 shares.